• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Blueprint Medicines Corp (BPMC)

Common Shares
Sell: $102.79|Buy: $108.41|Change: 0.42 (0.41%)

This share can be held in a Dealing accountISALifetime ISAJISASIPP

Company profile

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.

Address

45 Sidney Street
Cambridge
MA
USA
02139

Telephone

+1 617 7146674

Website

https://www.blueprintmedicines.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Blueprint Medicines Corp First Quarter Earnings Conference Call for 20252025-05-02T08:00:00
Blueprint Medicines Corp First Quarter Earnings Results for 20252025-05-02T00:00:00
Blueprint Medicines Corp Fourth Quarter Earnings Conference Call for 20242025-02-14T08:00:00
Blueprint Medicines Corp Fourth Quarter Earnings Results for 20242025-02-14T00:00:00
Blueprint Medicines Corp Annual Report for 20242025-02-14T00:00:00
Blueprint Medicines Corp Third Quarter Earnings Conference Call for 20242024-10-25T08:00:00
Blueprint Medicines Corp Third Quarter Earnings Results for 20242024-10-25T00:00:00
Blueprint Medicines Corp Second Quarter Earnings Conference Call for 20242024-08-02T08:00:00
Blueprint Medicines Corp Second Quarter Earnings Results for 20242024-08-02T00:00:00
Blueprint Medicines Corp Annual General Meeting for 20242024-06-21T15:30:00
Blueprint Medicines Corp First Quarter Earnings Conference Call for 20242024-05-02T08:00:00
Blueprint Medicines Corp First Quarter Earnings Result for 20242024-05-02T00:00:00

Previous key dates

NameKey Date
Blueprint Medicines Corp First Quarter Earnings Conference Call for 20242024-05-02T08:00:00
Blueprint Medicines Corp First Quarter Earnings Result for 20242024-05-02T00:00:00
Blueprint Medicines Conference Call 20242024-04-25T10:00:00
Blueprint Medicines Corp Fourth Quarter Earnings Conference Call for 20232024-02-15T08:00:00
Blueprint Medicines Corp Fourth Quarter Earnings Result for 20232024-02-15T00:00:00
Blueprint Medicines Corp Annual Report for 20232024-02-15T00:00:00
Blueprint Medicines Corp Third Quarter Earnings Conference Call for 20232023-10-26T08:00:00
Blueprint Medicines Corp Third Quarter Earnings Result for 20232023-10-26T00:00:00
Blueprint Medicines Corp Second Quarter Earnings Conference Call for 20232023-08-02T08:00:00
Blueprint Medicines Corp Second Quarter Earnings Result for 20232023-08-02T00:00:00
Blueprint Medicines Corp Annual General Meeting for 20232023-06-21T15:30:00
Blueprint Medicines Corp First Quarter Earnings Conference Call for 20232023-05-04T08:00:00
Blueprint Medicines Corp First Quarter Earnings Result for 20232023-05-04T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2024 AJ Bell. All rights reserved.